论文部分内容阅读
目的:研究分析低剂量沙利度胺联合地塞米松治疗老年初治多发性骨髓瘤的临床效果。方法:选取2012年9月至2015年9月在重庆市长寿区人民医院收治的54例老年初治多发性骨髓瘤患者,将其随机分为观察组和对照组,观察组采用低剂量沙利度胺联合地塞米松进行治疗,对照组采用标准VAD方案进行治疗,观察比较两组临床疗效及患者不良反应发生情况。结果:观察组总有效率为81.5%,与对照组的85.2%比较,差异无统计学意义(P>0.05);观察组各不良反应的发生率均明显低于对照组,差异具有统计学意义(P<0.05)。结论:低剂量沙利度胺联合地塞米松治疗老年初治多发性骨髓瘤疗效肯定,不良反应少。
Objective: To study the clinical effect of low dose thalidomide combined with dexamethasone in the treatment of multiple myeloma in the elderly. Methods: From September 2012 to September 2015, 54 elderly patients with newly diagnosed multiple myeloma who were admitted to Changshou District People’s Hospital of Chongqing were randomly divided into observation group and control group. The observation group was treated with low-dose Shali Degree of dexamethasone and dexamethasone for treatment. The control group was treated with standard VAD regimen. The clinical efficacy and adverse reactions of the two groups were observed and compared. Results: The total effective rate was 81.5% in the observation group and 85.2% in the control group, with no significant difference (P> 0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P <0.05). Conclusion: Low-dose thalidomide combined with dexamethasone treatment of elderly patients with multiple myeloma positive effect, less adverse reactions.